A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

Summary

The main objectives of the study were to evaluate the safety and tolerability of afamelanotide by measuring treatment emergent adverse events (AEs) and to determine whether afamelanotide can improve the quality of life of EPP patients.

Timeline

Start

2011-07-11

Primary completion

2014-02-27

Completion

2014-02-27

Drugs

Indications